Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | RUVBL1 | Q9Y265 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482959 | 1.00 | TACR1 (0.42) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL22482861 | 1.00 | TACR1 (0.42) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL18894572 | 1.00 | TACR1 (0.42) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL22482958 | 1.00 | TACR1 (0.42) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL24080578 | 0.91 | TACR1 (0.39) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL24080579 | 0.91 | TACR1 (0.39) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL18894570 | 0.89 | P2RY6 (0.48) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL22482843 | 0.83 | TACR1 (0.49) | TACR1MAPT | |
| SCHEMBL29478061 | 0.77 | KDM4E (0.52) | TACR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL18913375 | 0.77 | KDM4E (0.52) | TACR1KMT2AMEN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125820-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-28 | — | — | US | disclosed |
| US-11191774-B2 | Drug formulations for cancer treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200306284-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125820-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | RNMT, NTPCR, SYNCRIP | TACR1 4569/4885KMT2A 980/4885MEN1 220/4885 |
| US-20200306284-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | RNMT, NTPCR, SYNCRIP | TACR1 4569/4885KMT2A 980/4885MEN1 220/4885 |
| US-11191774-B2 | Drug formulations for cancer treatment | RNMT, NTPCR, SYNCRIP | TACR1 4569/4885KMT2A 980/4885MEN1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.